About this journal

Reliable data obtained from selective, sensitive and reproducible analysis of xenobiotics and biotics in biological samples is a fundamental and crucial part of every successful drug development program. The same principles can also apply to many other areas of research such as forensic science, toxicology and sports doping testing.

The bioanalytical field incorporates sophisticated techniques linking sample preparation and advanced separations with MS and NMR detection systems, automation and robotics. Standards set by regulatory bodies regarding method development and validation increasingly define the boundaries between speed and quality.

Bioanalysis is a progressive discipline for which the future holds many exciting opportunities to further reduce sample volumes, analysis cost and environmental impact, as well as to improve sensitivity, specificity, accuracy, efficiency, assay throughput, data quality, data handling and processing.

The journal Bioanalysis focuses on the techniques and methods used for the detection or quantitative study of analytes in human or animal biological samples. Bioanalysis encourages the submission of articles describing forward-looking applications, including biosensors, microfluidics, miniaturized analytical devices, and new hyphenated and multi-dimensional techniques.

Bioanalysis delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for the modern bioanalyst.

Principal themes include:

• Analyte extraction and sample preparation, including microsampling
• Chromatography and separation sciences
• MS, NMR and other key detection methods, including ligand binding assays
• Drug and metabolite assays
• Biomarker assays, diagnostic assays and test kits
• Method development and validation approaches
• Innovative bioanalytical methods and new instrumentation and equipment
• Laboratory automation and efficiency
• Regulatory and compliance issues
• Data processing and management

Audience

The content is uniquely targeted to those working on the bioanalysis of drugs, metabolites and endogenous substances in biological matrices. This is, primarily, bioanalysts working in pharmaceutical research and development in industry and academia, clinical laboratories, clinical toxicologists, forensic toxicologists and sports doping analysts. The articles will also have wide appeal to analytical chemists, pharmacologists, clinical chemists, and those involved with metabolomics studies.

The journal welcomes unsolicited article proposals.

Editor-in-chief

Spooner N, Spooner Bioanalytical Solutions Ltd, UK

Associate Editors

Anderson M, Merck and Co, Inc., USA
Borenstein MR, Temple University, PA, USA
Cape S, Labcorp, USA
Chaudhary AK, Merck and Co., Inc., PA, USA
Garg S, University of South Australia, Australia
Garofolo F, BRI Biopharmaceutical Research Inc, Canada
Hill H, Consultant, UK
Hodsdon ME, Eli Lilly & Company, USA
Musteata MF, Albany College of Pharmacy and Health Sciences, NY, USA
Staack RF, Roche Diagnostics GmbH, Germany
Wickremsinhe E, Gates MRI, USA
Zheng N, Bristol Myers Squibb, USA

International Editorial Advisory Board

Ackermann BL, Eli Lilly and Company, IN, USA
An HJ, Chungnam National University, Korea
Arnold M, Independent consultant, USA
Bateman K, Unaffiliated, USA
Bergquist J, Uppsala University, Sweden
Bhushan R, Indian Institute of Technology Roorkee, India
Bowers G, Xenofate Limited, United Kingdom
Bracewell DG, University College London, UK
Chang M, Biogen Idec, CA, USA
DeSilva B, Bristol-Myers Squibb, NJ, USA
DeStefano A, Allucent, Patel Kwan, USA
Dillen L, Janssen Research and Development, Belgium
Erve JCL, Elan, CA, USA
Fan LP, AbbVie, IL, USA
Foley JP, Drexel University, PA, USA
Gomez FA, California State University, CA, USA
Gorovits B, Pfizer Inc., USA
Gross E, Creighton University, NE, USA
Hage DS, University of Nebraska, USA
Haidar S, US FDA, USA
Halket JM, King’s College, London, UK
Hsieh Y, Merck, USA
Hutt AJ, University of Hertfordshire, Hertfordshire, UK
Islam I, Smithers, USA
Jensen BP, Canterbury Health Laboratories, New Zealand
Johnson MA, University of Kansas, KS, USA
Kamimori H, Shionogi & Co. Ltd., Japan
Katori N, National Institute of Health Sciences, Japan
Kole P, Queen's University Belfast, UK
Korfmacher W, Consultant, USA
Kumar, Prashant, University of Kansas, USA
Lee HS, Wonk Wang University, South Korea
Lu H, Chongqing University Innovative Drug Research Center, China
Li F, Biollege LLC, USA
Marcelín-Jiménez G, Global Bioanalytical Consulting, México
Mascini M, University of Firenze, Italy
Medvedovici A, University of Bucharest, Romania
Meier-Augenstein W, James Hutton Institute, UK
Meng M, Chongqing Denali Medpharma, Co., LtD, China
Mullangi R, Jubilant Biosys. Ltd, India
Niwa M, Nippon Kayaku Co., Ltd, Japan
Pamme N, The University of Hull, UK
Patel S, Janssen Research and Development, Pennsylvania, USA
Porta V, University of São Paulo, Brazil
Ramanathan R, Pfizer, Inc., USA
Roman GT, Waters Corporation, MA, USA
Schamasch P, International Olympic Committee, Switzerland
Shah VP, Independent Consultant, USA
Shankar G, Janssen R&D LLC (a company of Johnson & Johnson), PA, USA
Smith D, Independent, UK
Smith G, Unaffiliated, UK
Srinivas N, Longboard Pharmaceuticals, La Jolla, California, USA
Staack R, Roche Diagnostics GmbH, Germany
Stevenson D, University of Surrey, UK
Stevenson L, Immunologix Laboratories, USA
Szucs R, Pfizer, UK
Taghizadeh K, Massachusetts Institute of Technology, MA, USA
Tang D, United Power PharmaTech, China
Timmerman P, European Bioanalysis Forum, Belgium
Townsend D, Medical University of South Carolina, SC, USA
Trau D, National University of Singapore, Singapore
van de Merbel N, ICON, The Netherlands
Vuckovic D, Concordia University, Canada
Wang P, US FDA, USA
Weller MG, Federal Institute for Materials Research and Testing (BAM), Germany
Wright P, University of Greenwich, UK
Xu F, China Pharmaceutical University, China
Zhang J, US FDA, USA
Zhou M, Pars Pharma Consulting, USA